



### **Session 3 – Broadening the scope: should we stick to only lung cancer, CT and smokers, or is there more?**

*Chairs: Harry De Koning (Netherlands)*

- |             |   |
|-------------|---|
| 14.00-14.30 | Added value beyond lung cancer screening<br><i>Hans-Ulrich Kauczor (Germany)</i>  |
| 14.30-15.00 | Who should we screen beyond (ex-) smokers<br><i>Jan van Meerbeeck (Belgium)</i>   |
| 15.00-15.30 | Breathomics: an extra nose to detect lung cancer?<br><i>Marc van der Schee (Netherlands)</i>  |
| 15.30-16.00 | Blood biomarkers: ready for practice?<br><i>John Field (UK)</i>   |
| 16.00-16.30 | Discussion  |
| 16.30-16.45 | Coffee break  |
| 16.45-17.45 | <b>Breakout sessions</b><br><br>Group 1: Epidemiologic implementation<br><i>Chairs: Guido van Hal and Harry De Koning</i><br>Discussion of the possible solutions, strategies and research opportunities to target the hard-to-reach population<br><br>Group 2: Technical implementation<br><i>Chairs: Annemie Snoeckx and Hans-Ulrich Kauczor</i><br>Discussion of the numerous aspects that need to be addressed before lung cancer screening can be implemented in daily practice<br><br>Group 3: Dilemma's in lung cancer screening<br><i>Chairs: Jan Van Meerbeeck and Bert van Herk</i> |
| 17.45-18.15 | Report from break out groups and closing remarks of day 1   |

### **Wednesday, 12 December 2018**

#### **Session 4 – From trial to practice: concerns of different stakeholders**

*Chairs: John Field and Hans-Ulrich Kauczor*

- |             |  |
|-------------|--|
| 08.30-09.00 | What to do with all those pulmonary nodules: the pulmonologist's view<br><i>Nina Bostantzoglou (Greece)</i>        |
| 09.00-09.30 | How will lung cancer screening impact our daily practice? A radiologist's view<br><i>Annemie Snoeckx (Belgium)</i> |

09.30-10.00	The surgeon's point of view <i>Anna Elisabeth Frick (Belgium)</i>
10.00-10.30	General discussion
10.30-11.00	<i>Coffee break</i>
11.00-11.30	Artificial Intelligence: an extra clinician we can not ignore <i>Bram Van Ginneken (Netherlands)</i>
11.30-12.00	Report of ongoing trials <i>John Field (UK)</i>
12.00-12.30	ERS-ESR White Paper on Lung Cancer Screening <i>Hans-Ulrich Kauczor (Germany)</i>
12.30-13.00	Remarks, conclusions and action points
13.00	Lunch and farewell